UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1

Gastroenterology (New York, N.Y. 1943), 2019-05, Vol.156 (6), p.1849-1861.e13

2019

Volltextzugriff (PDF)

Venetoclax in combination with nucleoside analogs in acute myelogenous leukemia

Current opinion in oncology, 2022-09, Vol.34 (5), p.531-539

2022

Volltextzugriff (PDF)

High-Risk Mantle Cell Lymphoma in the Era of Novel Agents

Current hematologic malignancy reports, 2021-02, Vol.16 (1), p.8-18

2021

Volltextzugriff (PDF)

A Clinical Review of the Different Strategies to Minimize Hemorrhagic Cystitis Associated with the Use of Post-Transplantation Cyclophosphamide in an Allogeneic Transplant

Transplantation and cellular therapy, 2022-07, Vol.28 (7), p.349-354

2022

Volltextzugriff (PDF)

GATA3 rs3824662A allele in B‐cell acute lymphoblastic leukemia in adults, adolescents and young adults: association with CRLF2 rearrangement and poor prognosis

American journal of hematology, 2021-03, Vol.96 (3), p.E71-E74

2021

Volltextzugriff (PDF)

Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship

Cancer, 2017-02, Vol.123 (4), p.609-616

2017

Volltextzugriff (PDF)

Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models

Haematologica (Roma), 2020-03, Vol.105 (3), p.697-707

2020

Volltextzugriff (PDF)

Inhibition of Galectin-9 sensitizes tumors to anthracycline treatment via inducing antitumor immunity

International journal of biological sciences, 2023-01, Vol.19 (14), p.4644-4656

2023

Volltextzugriff (PDF)

P688: ASC2ESCALATE: A US PHASE 2, OPEN‐LABEL, SINGLE‐ARM, DOSE‐ESCALATION STUDY OF ASCIMINIB MONOTHERAPY IN 2ND‐LINE (2L) TREATMENT OF PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML‐CP)

HemaSphere, 2023-08, Vol.7 (S3), p.e8144284-n/a

2023

Volltextzugriff (PDF)

PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunity

Journal for immunotherapy of cancer, 2023-10, Vol.11 (10), p.e006619

2023

Volltextzugriff (PDF)

Inhibition of c-MET upregulates PD-L1 expression in lung adenocarcinoma

American journal of cancer research, 2020-01, Vol.10 (2), p.564-571

2020

Volltextzugriff (PDF)

Use of monoclonal antibody therapy in hematologic patients with mild‐to‐moderate COVID‐19: A retrospective single‐center experience

Cancer medicine (Malden, MA), 2023-05, Vol.12 (10), p.11248-11253

2023

Volltextzugriff (PDF)

Asymmetric Weakness and West Nile Virus Infection

The Journal of emergency medicine, 2015-09, Vol.49 (3), p.274-276

2015

Volltextzugriff (PDF)

Development and Validation of a Novel Stratification Tool for Identifying Cancer Patients at Increased Risk of Surgical Site Infection

Annals of surgery, 2012, Vol.255 (1), p.134-139

2012

Volltextzugriff (PDF)

Ponatinib, asciminib and inotuzumab ozogamicin: A novel drug combination in acute lymphoblastic leukemia

Leukemia research, 2023-06, Vol.129, p.107299-107299, Article 107299

2023

Volltextzugriff (PDF)

Cladribine, Cytarabine, and Etoposide-Based Regimens Are Safe and Tolerable In Relapsed and Refractory Acute Myeloid Leukemia Patients

Acta haematologica, 2023-11, Vol.146 (6), p.538-542

2023

Volltextzugriff (PDF)

Treatment Outcomes of Acute Myeloid Leukemia in Patients Living with Human Immunodeficiency Virus Receiving Antiretroviral Therapy: A Single-Center Experience

Acta haematologica, 2023-11, Vol.146 (6), p.490-495

2023

Volltextzugriff (PDF)

Covalent-103: A Phase 1, Open-Label, Dose-Escalation, and Dose-Expansion Study of Bmf-500, an Oral Covalent FLT3 Inhibitor, in Adults with Acute Leukemia (AL)

Blood, 2023-11, Vol.142 (Supplement 1), p.1546-1546

2023

Volltextzugriff (PDF)

Delaying Pegaspargase Administration during Induction in Adults with Acute Lymphoblastic Leukemia

Blood, 2023-11, Vol.142 (Supplement 1), p.4239-4239

2023

Volltextzugriff (PDF)

Concurrent Versus Sequential or No Triazole Anti-Fungal Therapy in Patients Undergoing 7+3 Plus Midostaurin Induction for FLT-3 Acute Myelogenous Leukemia

Blood, 2023-11, Vol.142 (Supplement 1), p.5932-5932

2023

Volltextzugriff (PDF)

ASC2ESCALATE: A US Phase 2, Open-Label, Single-Arm, Dose-Escalation Study of Asciminib (ASC) Monotherapy in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) As Second-Line (2L) and First-Line (1L) Treatment

Blood, 2023-11, Vol.142 (Supplement 1), p.6389-6389

2023

Volltextzugriff (PDF)

ASC2ESCALATE: A US phase 2, single-arm, dose-escalation study of asciminib monotherapy in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with 1 prior tyrosine kinase inhibitor (TKI)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS7082-TPS7082

2023

Volltextzugriff (PDF)

ASC2ESCALATE: A Phase 2, Single-Arm, Dose-Escalation Study of Asciminib Monotherapy in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with 1 Prior Tyrosine Kinase Inhibitor (TKI)

Blood, 2022-11, Vol.140 (Supplement 1), p.6784-6786

2022

Volltextzugriff (PDF)

Preliminary Results from a Phase 2 Open-Label, Multicenter, Dose Optimization Clinical Study of the Safety, Tolerability, and Pharmacokinetic (PK) and Pharmacodynamic (PD) Profiles of Cfi-400945 As a Single Agent or in Combination with Azacitidine or Decitabine in Patients with Acute Myeloid Leukemia, Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (TWT-202)

Blood, 2022-11, Vol.140 (Supplement 1), p.9076-9077

2022

Volltextzugriff (PDF)

Treatment of relapsed or refractory FLT-3 acute myelogenous leukemia with a triplet regimen of hypomethylating agent, venetoclax, and gilteritinib

Leukemia & lymphoma, 2024-03, Vol.65 (3), p.372-377

2024

Volltextzugriff (PDF)

1 – 25 von 727

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(456)
Mit Volltextzugriff
(626)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(12)

Menü

Weitere Dienste

Einstellungen

MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1

Venetoclax in combination with nucleoside analogs in acute myelogenous leukemia

High-Risk Mantle Cell Lymphoma in the Era of Novel Agents

A Clinical Review of the Different Strategies to Minimize Hemorrhagic Cystitis Associated with the Use of Post-Transplantation Cyclophosphamide in an Allogeneic Transplant

GATA3 rs3824662A allele in B‐cell acute lymphoblastic leukemia in adults, adolescents and young adults: association with CRLF2 rearrangement and poor prognosis

Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship

Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models

Inhibition of Galectin-9 sensitizes tumors to anthracycline treatment via inducing antitumor immunity

P688: ASC2ESCALATE: A US PHASE 2, OPEN‐LABEL, SINGLE‐ARM, DOSE‐ESCALATION STUDY OF ASCIMINIB MONOTHERAPY IN 2ND‐LINE (2L) TREATMENT OF PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML‐CP)

PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunity

Inhibition of c-MET upregulates PD-L1 expression in lung adenocarcinoma

Use of monoclonal antibody therapy in hematologic patients with mild‐to‐moderate COVID‐19: A retrospective single‐center experience

Asymmetric Weakness and West Nile Virus Infection

Development and Validation of a Novel Stratification Tool for Identifying Cancer Patients at Increased Risk of Surgical Site Infection

Ponatinib, asciminib and inotuzumab ozogamicin: A novel drug combination in acute lymphoblastic leukemia

Cladribine, Cytarabine, and Etoposide-Based Regimens Are Safe and Tolerable In Relapsed and Refractory Acute Myeloid Leukemia Patients

Treatment Outcomes of Acute Myeloid Leukemia in Patients Living with Human Immunodeficiency Virus Receiving Antiretroviral Therapy: A Single-Center Experience

Covalent-103: A Phase 1, Open-Label, Dose-Escalation, and Dose-Expansion Study of Bmf-500, an Oral Covalent FLT3 Inhibitor, in Adults with Acute Leukemia (AL)

Delaying Pegaspargase Administration during Induction in Adults with Acute Lymphoblastic Leukemia

Concurrent Versus Sequential or No Triazole Anti-Fungal Therapy in Patients Undergoing 7+3 Plus Midostaurin Induction for FLT-3 Acute Myelogenous Leukemia

ASC2ESCALATE: A US Phase 2, Open-Label, Single-Arm, Dose-Escalation Study of Asciminib (ASC) Monotherapy in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) As Second-Line (2L) and First-Line (1L) Treatment

ASC2ESCALATE: A US phase 2, single-arm, dose-escalation study of asciminib monotherapy in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with 1 prior tyrosine kinase inhibitor (TKI)

ASC2ESCALATE: A Phase 2, Single-Arm, Dose-Escalation Study of Asciminib Monotherapy in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with 1 Prior Tyrosine Kinase Inhibitor (TKI)

Treatment of relapsed or refractory FLT-3 acute myelogenous leukemia with a triplet regimen of hypomethylating agent, venetoclax, and gilteritinib

Suchergebnisse filtern